Sanofi (SNY)
| Market Cap | 99.44B -20.7% |
| Revenue (ttm) | 55.89B +7.0% |
| Net Income | 4.52B -56.6% |
| EPS | 1.83 -55.6% |
| Shares Out | 1.20B |
| PE Ratio | 22.75 |
| Forward PE | 8.71 |
| Dividend | $2.42 (5.82%) |
| Ex-Dividend Date | May 4, 2026 |
| Volume | 2,011,454 |
| Open | 41.70 |
| Previous Close | 41.96 |
| Day's Range | 41.33 - 41.75 |
| 52-Week Range | 39.07 - 52.68 |
| Beta | 0.28 |
| Analysts | Buy |
| Price Target | 53.61 (+28.87%) |
| Earnings Date | Oct 30, 2026 |
About SNY
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection; hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines; and Fluzone, a flu vaccine. It has a collaboration and license agreement with Exscientia to develop small-molecu... [Read more]
Financial Performance
In 2025, Sanofi's revenue was 46.72 billion, an increase of 5.49% compared to the previous year's 44.29 billion. Earnings were 7.81 billion, an increase of 40.52%.
Financial numbers in EUR Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for SNY stock is "Buy." The 12-month stock price target is $53.61, which is an increase of 28.87% from the latest price.
News
These French Companies Have Global Reach. The Stocks Are Bargains.
Some investors are looking beyond turmoil in France for companies that depend little on their domestic market.
Teva/Sanofi: Duvakitug Maintains Meaningful Efficacy Improvements In Long-term Extension Study
PETAH TIKVA (dpa-AFX) - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries (TEVA), and Sanofi announced new positive data from the RELIEVE UCCD phase 2b long-term extension s...
Teva: Duvakitug Maintains Meaningful Efficacy Improvements In Long-term Extension Study
PETAH TIKVA (dpa-AFX) - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries (TEVA), and Sanofi announced new positive data from the RELIEVE UCCD phase 2b long-term extension s...
Is It Too Late to Buy Sanofi SA (SNY) After 4.6% Rally? GF Value Says Undervalued
Is It Too Late to Buy Sanofi SA (SNY) After 4.6% Rally? GF Value Says Undervalued
Teva, Sanofi Report Sustained Duvakitug Benefits In Phase 2b IBD Study
(RTTNews) - Teva Pharmaceutical Industries Ltd. (TEVA) and Sanofi (SNY) announced positive long-term Phase 2b data for investigational duvakitug, showing sustained improvements in ulcerative colitis (...
Sanofi, ScionxBio enter collaboration, licensing agreement
ScionxBio has entered into a worldwide strategic collaboration and licensing agreement with Sanofi (SNY) to develop and commercialize extended exposure versions of certain Sanofi mRNA candidates by le...
ScionxBio Announces Collaboration to Develop Long-Acting xRNA Therapeutics
CAMBRIDGE, England--(BUSINESS WIRE)--ScionxBio (the “company”, operating as a brand identity of Eleven Therapeutics Ltd. following a horizontal split) a privately held, preclinical-stage biotechnology...
Teva Pharmaceutical Industries Ltd: UEG Week: Teva and Sanofi's Duvakitug Maintained Long-Term Positive Outcomes in New Phase 2b Data for Ulcerative Colitis and Crohn's Disease
In UC, duvakitug maintained high rates of clinical remission, clinical response, and endoscopic improvement at Week 44In CD, duvakitug maintained high rates of endoscopic response, clinical respons...
Sanofi Commences Construction Of Insulin Facility In Frankfurt, Germany
(RTTNews) - Monday, Sanofi (SNY) commenced construction of a new state-of-the-art insulin manufacturing facility at its BioCampus in Frankfurt, Germany, leveraging advanced digital technologies and ar...
Enable Injections Announces Approval in Japan for CirCLIQ® Injector based on enFuse® On-Body Delivery System
Sanofi's CirCLIQ® Injector, developed using enFuse technology, has been approved to administer Sarclisa subcutaneous formulation, in combination with approved standard-of-care regimens, for patients w...
Sanofi (SNY) Begins Construction of New Insulin Manufacturing Facility in Frankfurt
Sanofi (SNY) Begins Construction of New Insulin Manufacturing Facility in Frankfurt
Sanofi: Sanofi breaks ground on new state-of-the-art insulin manufacturing facility in Germany
Sanofi breaks ground on new state-of-the-art insulin manufacturing facility in Germany Paris and Frankfurt, October 19, 2026. Sanofi today broke ground on a new state-of-the-art insulin manufacturi...
Press Release: Sanofi breaks ground on new state-of-the-art insulin manufacturing facility in Germany
Sanofi breaks ground on new state-of-the-art insulin manufacturing facility in Germany Paris and Frankfurt, October 19, 2 026. Sanofi today broke ground on a new state-of-the-art insulin manufacturing...
Sanofi price target lowered to EUR 75 from EUR 800 at RBC Capital
RBC Capital lowered the firm’s price target on Sanofi (SNY) to EUR 75 from EUR 800 and keeps a Sector Perform rating on the shares ahead of its Q3 results.
Sanofi, PCPA Sign LOI For Dupixent Across Four Additional Indications
(RTTNews) - Sanofi (SNY) said Thursday it has completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) and signed a letter of intent, or LOI for Dupixent across four additional indi...
Recursion Pharmaceuticals Stock (RXRX) Soars 15% on a $10M Milestone Payment from Sanofi
Recursion Pharmaceuticals stock gained nearly 15% on Thursday thanks to a drug candidate update and milestone payment.
Sanofi, pCPA sign letter of intent for Dupixent across four indications
Sanofi (SNY) announced the successful completion of negotiations between the pan-Canadian Pharmaceutical Alliance and Sanofi with a signed Letter of Intent for Dupixent for four additional indications...
Recursion To Receive $10 Mln Milestone Payment As Sanofi Selects Immunology Drug Candidate
(RTTNews) - Recursion Pharmaceuticals Inc. (RXRX) announced Thursday that Sanofi (SNY) has selected the first development candidate under their research collaboration, triggering a $10 million milesto...
Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration
Potential first-in-class dual targeting inhibitor oral small molecule to enter Sanofi’s development pipeline, with phase 1 clinical study currently planned to begin in 2027 Salt Lake City, UT, Oct. 15...
European Commission Accepts Makes Sanofi's Commitments Legally Binding On Flu Vaccine Practices
(RTTNews) - Wednesday, the European Commission has made commitments offered by Sanofi (SNY) legally binding under EU antitrust rules.
Sanofi (SNY) Avoids EU Fine with Commitments on Vaccine Marketing Practices
Sanofi (SNY) Avoids EU Fine with Commitments on Vaccine Marketing Practices
Sanofi Resolves EU Antitrust Investigation with Binding Commitments
Sanofi Resolves EU Antitrust Investigation with Binding Commitments
European Commission Enforces Sanofi's Commitments on Antitrust Concerns (SNY)
European Commission Enforces Sanofi's Commitments on Antitrust Concerns (SNY)
EU accepts Sanofi’s concessions to end probe over vaccine marketing
The European Commission has made commitments offered by Sanofi (SNY) legally binding under EU antitrust rules. The commitments relate to the Commission’s preliminary competition concerns relating to S...
EU Accepts Sanofi's Concessions to Settle Antitrust Probe Over Vaccine Marketing
Sanofi's offer to rectify the potential effects of its past messages on a rival flu shot awould address concerns, the bloc's executive arm said.